ArrowheadPharma
@ArrowheadPharma
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them.
What if #RNAi isn’t just a tool, but a turning point in how we treat complex diseases? At Arrowhead, we’re leading the way with our TRiM™ platform to develop targeted, durable therapies. Explore how we’re shaping the future of medicine bit.ly/45WMXba #PrecisionMedicine
Attending #ENDO25? Visit booth 825 to meet our team and learn how advances in #lipid and #triglyceride management are helping shape the future of #cardiometabolic care. Let’s connect on the latest guidelines, current research, and innovations in patient-centered care.
Will you be at @HeartinDiabetes in Philadelphia? Find us to discuss how emerging science is shaping clinical guidelines for lipid disorder management and advancing #cardiometabolic care. #HeartInDiabetes
We’ve issued a statement on our agreement with Sarepta Therapeutics. To learn more, read the full press release here: bit.ly/3IBKU2V
Save the date for our upcoming fiscal 2025 third quarter earnings call. Join our live webcast and conference call on August 7, 2025, at 4:30pm ET to discuss our #FinancialResults. Read more in our press release: bit.ly/4lYAecI
Katherine Kramer, Senior Medical Science Liaison at Arrowhead, is at #ENDO25 sharing insights on advancing #lipid & #triglyceride care and its impact on #cardiometabolic health. Visit booth 825 to explore the latest science & innovations in patient-centered care. #Endocrinology
We’re pleased to announce the initiation of our Phase 3 YOSEMITE #ClinicalTrial using our #RNAi- targeting therapies to treat Homozygous Familial Hypercholesterolemia (#HoFH). Read more in our press release: bit.ly/45ZCk7A
Today we announced we completed enrollment for studies in our Phase 3 #ClinicalTrials designed to support regulatory submissions for marketing approval for the treatment of severe hypertriglyceridemia. Read more in our press release: bit.ly/4k6WDn9
Today, our 4 US sites are walking the @LivingWithFCS Virtual 5K to raise awareness for Familial Chylomicronemia Syndrome—a rare disease affecting as few as 1 in a million. 💙 We walk to fight for patients & families. Share your story: bit.ly/4jPshoS #FCS2025k
🏃Let’s go the distance to raise awareness of Familial Chylomicronemia Syndrome (FCS). Join us in walking the @LivingWIthFCS Virtual 5K on 6/11 — from anywhere. We’re a proud sponsor of the walk and will see you out there. bit.ly/4dQUEBR #FCS2025K
Today we announced the initiation of our Phase 1/2a #ClinicalTrial of our #RNAi therapeutic as a potential treatment for #Obesity. Read more in our press release: bit.ly/4klELFM
What’s next in RNAi science for lipid & cardiometabolic conditions? Arrowhead is proud to have 4 abstracts accepted at the 2025 @NationalLipid Association Scientific Sessions. See the agenda: bit.ly/3FsQL9u #NLASessions #RNAi #CardiometabolicHealth
We’re attending two upcoming fireside chat presentations in June! Join us on June 4th at @Jefferies Global Healthcare Conference & on June 9th at the @GoldmanSachs 46th Annual Global Healthcare Conference. More in our press release: bit.ly/43zfJvJ #JefferiesHealthcare
Are you ready to discuss all things lipids in Miami at the #NLASessions this weekend? Come find Andy Davis and our Arrowheads at booth #207 to learn more about the NLA Guidelines for lipid and #triglyceride management. #WeAreArrowhead #ForFCS #NLA25
On #ClinicalTrialsDay, we recognize the power of partnership in advancing clinical research. Thank you to the patients, caregivers, and investigators driving #RNAi -based investigational therapies forward. These trials bring us closer to meaningful treatments for rare diseases.
Curious about the latest clinical guidance on triglycerides? Visit us at booth #230 at #AACE2025 in Orlando this weekend. We’re sharing updated recommendations for managing patients with elevated triglyceride levels and how these strategies may improve patient care.
Today we reported our fiscal 2025 second quarter results. Tune in to our webcast replay and read our press release to learn more: bit.ly/4iYDJOs $ARWR
AT #ESPEESE2025? Visit Arrowhead at Booth E.04 to explore how #RNAi is advancing clinical development in #cardiometabolic care. We're excited to connect and share how we're driving innovation to improve patient outcomes. #WeAreArrowhead #Endocrinology
We’re excited to participate in two upcoming fireside chats in May! Join us on May 14th for the @BankofAmerica Securities Healthcare Conference and on May 20th for the @RBCCM Global Healthcare Conference. Read more in our press release: bit.ly/42MszHX
Heading to #EAS2025? Visit us at booth 22 to explore how #RNAi therapeutics have the potential to transform care for patients with complex #lipid disorders. We're excited to discuss how our clinical development programs are advancing #CardiometabolicCare. #Cardiology